DFTX Definium Therapeutics, Inc.
FY2025 10-K
Definium Therapeutics, Inc. (DFTX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
- • New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
Management Discussion & Analysis
- • No revenue or profitability data disclosed in the provided MD&A excerpt
- • No segment performance or financial results reported
Risk Factors
- • Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
- • Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
Financial SummaryXBRL
Net Income
-$184M
ROE
-55.3%
Total Assets
$440M
EPS (Diluted)
$-2.06
Operating Cash Flow
-$132M
Source: XBRL data from Definium Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Definium Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.